Movers and Shakers

ABLi Therapeutics has appointed founder Milton Werner as founding CEO

Cellarity has appointed Ted Myles as CEO

Compugen is planning for CEO Anat Cohen-Dayag to pivot to the newly created role of Executive Chair of the Board of Directors; current Chief Scientific Officer Eran Ophir will assume the role of CEO

CRO Fortrea founding CEO Thomas Pike has stepped down with Independent Director Peter Neupert stepping in as Interim CEO

NGM Bio CEO David Woodhouse has stepped down with VP of Corporate Development Diana Peng Bockus taking his place

Novo Nordisk CEO Lars Fruergaard Jørgensen has stepped down; the company has accelerated the search for his successor

Stylus Medicine has appointed Emile Nuwaysir as founding CEO and Jason Fontenot as founding Chief Scientific Officer

VERAXA Biotech has appointed Rick Austin as Chief Scientific Officer

vTv Therapetucis has appointed Michael Tung as Executive Vice President and CFO

Trailhead Biosystems has appointed David Llewelln as CEO and Director

Alloy Therapeutics has appointed Victor Stone as CEO

Innate Pharma has appointed Jonathan Dickinson as CEO and Director and Irina Staatz-Granzer as Chairman

Diamyd Medical has appointed Niklas Axelsson as CFO

Schrodinger has appointed Richie Jain as CFO

Shift Bioscience has appointed Lord David Prior as Chairman

Cinclus Pharma has appointed Lennart Hansson as Chairman